Adults at least 18 years old and not more than 65 years of age with a clinical diagnosis of moderate to severe chronic plaque psoriasis with a disease duration of at least 6 months, may qualify to participate. Individuals must have 10% or more body surface area (BSA) affected by plaque psoriasis, and have no other skin disease which may interfere with assessment of chronic plaque psoriasis.
Participants will receive investigational oral medication (active study drug) or placebo. Study medication and study-related assessments will be provided at no cost.
Study participation will last about 24 weeks and involve about 8 visits to the study centre, plus a follow-up phone call.